Dexcom Q3 revenue $1.209B (+22% YoY); raises FY 2025 revenue guidance to $4.63-4.65B

DEXCOM INC

2025-Q3 EPS reported $1.42 revenue$3,402,400,000

GAAP EPS $0.70 vs $0.34 YoY; non-GAAP EPS $0.61 vs $0.45 YoY.
U.S. revenue +21% YoY; international revenue +22% reported, +18% organic.
GAAP operating margin 20.1% (480 bps improvement); non-GAAP operating margin 22.6%.
Stelo surpassed $100M revenue in first 12 months; submitted Dexcom Smart Basal to FDA.
Cash and marketable securities $3.32B; revolver undrawn.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.